Drug intelligence / Profile preview

BIBP-Rec-Vaccine

Development stage: Phase 3
Lead developer: National Vaccine and Serum Institute
Modality: Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

BIBP-Rec-Vaccine is a recombinant COVID-19 vaccine, specifically a CHO cell-derived recombinant vaccine (NVSI-06-09). Developed by the National Vaccine and Serum Institute, China, it is currently undergoing a randomized, double-blind, placebo-controlled Phase III clinical trial. The vaccine is being evaluated for its efficacy, safety, and immunogenicity as a booster dose in healthy individuals aged 18 and above who have previously received at least two doses of either an inactivated COVID-19 vaccine or an mRNA COVID-19 vaccine.

Brand names: LIBP-Rec-VaccineBIBP-Rec-Vaccine
Other names: BIBP Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09)

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on BIBP-Rec-Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIBP-Rec-Vaccine.

Explore the full profile